onclive·May 7·1 min readsaveCo-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy ResponseMay 7, 2026·read at onclive ↗Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.sourceReporting by onclive.read at onclive ↗sharecopy linkx / twitterlinkedinmore…
comments(0)
5-min edit window · permanent after that